A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma by Kumar, Anita, Soumerai, Jacob, Abramson, Jeremy S., Barnes, Jeffrey A., Caron, Philip, Chabowska, Maria, Devlin, Mary, Dogan, Ahmet, Falchi, Lorenzo, Garcia, Rayna N., Grieve, Clare, Haskell, Emma, Haydu, Julie E., Johnson, Patrick Connor, Joseph, Ashlee, Kelly, Hailey E., Labarre, Alyssa, Littlejohn, Emerald D, Lue, Jennifer Kimberly, Mi, Joanna, Martignetti, Rosalba, McCambridge, Grace, Moskowitz, Alison, Owens, Colette, Plummer, Sean F., Puccio, Madeline G., Salles, Gilles, Seshan, Venkatraman, Slupe, Natalie, Zelenetz, Andrew D.

Get full text